Alps Advisors Inc. boosted its stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 54.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 53,767 shares of the specialty pharmaceutical company’s stock after acquiring an additional 19,015 shares during the period. Alps Advisors Inc.’s holdings in AMAG Pharmaceuticals were worth $712,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of AMAG. State Street Corp raised its holdings in AMAG Pharmaceuticals by 10.6% in the 2nd quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock valued at $51,336,000 after buying an additional 267,873 shares during the period. Tocqueville Asset Management L.P. purchased a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at about $3,958,000. Prudential Financial Inc. raised its holdings in AMAG Pharmaceuticals by 35.7% in the 3rd quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after buying an additional 190,660 shares during the period. Dimensional Fund Advisors LP raised its holdings in AMAG Pharmaceuticals by 18.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock valued at $22,361,000 after buying an additional 189,576 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its holdings in AMAG Pharmaceuticals by 46.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock valued at $7,839,000 after buying an additional 134,080 shares during the period.

Shares of AMAG Pharmaceuticals, Inc. (AMAG) opened at $12.95 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. The stock has a market cap of $456.98, a PE ratio of -2.13 and a beta of 0.79. AMAG Pharmaceuticals, Inc. has a one year low of $11.93 and a one year high of $25.20.

Several analysts recently issued reports on AMAG shares. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Piper Jaffray Companies started coverage on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price objective on the stock. Morgan Stanley reduced their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Finally, Jefferies Group restated a “buy” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $19.89.

COPYRIGHT VIOLATION WARNING: “Alps Advisors Inc. Has $712,000 Stake in AMAG Pharmaceuticals, Inc. (AMAG)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2018/02/12/alps-advisors-inc-has-712000-stake-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.